Our new website is coming soon, give it a try now and let us have your feedback. Take me to the Beta



Register
Login:
Share:
Email Facebook Twitter


TSX Lithium explorer International Lithium Corp prepares to drill at Raleigh Lake
Exclusive: Hardman & Co Investor Forum - Severn Trent, Calculus Capital, Volta Finance, Residential




Share Price Information for Summit Ther (SUMM)


Share Price: 23.75Bid: 22.50Ask: 25.00Change: -1.25 (-5.00%)Faller - Summit Ther
Spread: 2.50Spread as %: 11.11%Open: 24.50High: 24.50Low: 23.75Yesterday’s Close: 25.00

Summit Therapeutics Plc Ord 1P

Summit Ther is listed in the FTSE AIM All-Share
Summit Ther is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
23.75
Share Price SpacerBid
22.50
Share Price SpacerAsk
25.00
Share Price SpacerChange
-5%-1.25
Share Price SpacerVolume
48,934
Share Price SpacerOpen
24.50
Share Price SpacerHigh
24.50
Share Price SpacerLow
23.75
Share Price SpacerClose
25.00
Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 160.49m £38.12m 3,000

52 Week High 200.00 52 Week High Date 26-JUN-2018
52 Week Low 17.00 52 Week Low Date 14-DEC-2018

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
12 23,359 25,575 5.061 4.69 0.00 0.00


London South East Users info for Summit Ther




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

19-Jun-19
14:34:31
24.11
8,243
Buy* 
22.50
25.00
1,987
Trade Type:
Ordinary

19-Jun-19
13:33:01
23.21
1,650
Sell* 
22.50
25.00
382.97
Trade Type:
Ordinary

19-Jun-19
13:11:37
23.21
87
Sell* 
22.50
25.00
20.19
Trade Type:
Ordinary




View more Summit Ther trades >>

Directors Deals for Summit Ther (SUMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
23-Apr-19Transfer From
Trade Notifier Information for Summit Therapeutics
Frank Armstrong held the position of Non-Executive Chairman at Summit Therapeutics at the time of this trade.
 Frank Armstrong
036,585158789
23-Apr-19Transfer From
Trade Notifier Information for Summit Therapeutics
Valerie Andrews held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 Valerie Andrews
017,07366196
23-Apr-19Transfer From
Trade Notifier Information for Summit Therapeutics
David Wurzer held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 David Wurzer
017,07363196
View more Summit Ther directors dealings >>


Chrisatrdg
Posts: 1,526
Opinion:Strong Buy
Price:23.75
AGM Update
Today 15:53
Per waterloo01 from the other board:
Quick AGM update.

Lots of talk about the different approach to antibiotics, in going for both superiority and presenting the economic case. Many of the recent failures in the space have a lot to do with the fact most are going for equivalence/me too products.

There are only 8 antibiotics currently in phase 1-3 that are new mechanism if actions, RDZ being one of them

Are about 100 sites currently open (Clinical trials lists 2 but apparently is out of date). Results still planned mid 2021.

Barda relationship is good and possibility of some more from them but there is a funding gap which is estimated to be between $60m and $100m over 2 years.

Most likely this will be raised from equity and one has the feeling they have somethings lined up. Stressed point that last placing was at a premium, so hopefully that's repeated. Dungan continues to be supportive and likely to come in on any further raises.

Push and pull incentives are important, but because of their approach (superiority)they will build an economic case regardless. However the current bill going through US congress (Disarm) could make a massive difference as will pay hospital 102% of the cost of the drug (are other initiatives ongoing as well). Might this be the thing that will change the whole investment environment?

Still suggesting market could be worth $1bn US alone (they want to keep US rights but might other geographies be part of any funding?) and if adopted RDZ should save hospitals $3 bn a year.

Other antibiotics all going to plan.

So in short, an exciting future but further funding needed, but the end prize remains significant and ever more so as and when the investing community start to reinvest in the area (and Disarm act might be the thing that makes the difference here).

More if I remember. Good to meet the other investors.
Merlin0
Posts: 197
Opinion:No Opinion
Price:23.75
Summ
Today 09:42
I thought that this bit of news about additional funds would have put a rocket on the share price?Good old aim
Merlin0
Posts: 197
Opinion:No Opinion
Price:23.75
Summ
Today 09:03
What other news on the horizon??
Merlin0
Posts: 197
Opinion:No Opinion
Price:23.75
Summ
Today 08:11
Boom times ahead
Nice rns yesterday
Hawkander
Posts: 595
Opinion:No Opinion
Price:25.00
Buy?
Tue 21:43
Any thoughts of a potential buyout by one of the majors, with what`s on offer here at this stage, just a thought? GLA
View more share chat for Summit Ther (SUMM) >>







Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk









Home  |  Contact Us  |  About Us  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy  |  Mobile Site  |  About this website design


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.